Core Viewpoint - Lianchi Hospital Group Co., Ltd. has submitted its prospectus and is preparing for an IPO on the Hong Kong Stock Exchange [2]. Financial Performance - For the nine months ending September 30, 2025, Lianchi Hospital reported revenue of RMB 359 million, gross profit of RMB 128 million, and net profit of RMB 55.51 million [3][4]. - Projected revenues for 2023 and 2024 are RMB 356 million and RMB 418 million, respectively, with gross profits of RMB 117 million and RMB 151 million [4]. - Operating profits for the same periods are expected to be RMB 69.69 million and RMB 88.16 million, with net profits of RMB 56.73 million and RMB 67.59 million [4]. Business Model and Strategy - Lianchi Hospital focuses on the "one elderly, one child" high-potential sector, implementing a "people-centered medical" management model [3]. - The hospital group operates five hospitals and one elderly care institution, offering specialized medical services such as pain management and rapid recovery [3]. Shareholding Structure - Chen Zhiqiang controls 46.86% of the shares through Zhongya Investment, with other significant shareholders including Zheng Guosen and Nanjing Ruipi Enterprise Management [10][12]. - The executive team includes Chen Zhiqiang as the chairman and Zhu Meiling as the president, who has over 30 years of experience in obstetrics and hospital management [6][8].

Company Overview - Lianchi Hospital Group Co., Ltd. is a specialty medical group in China, operating five hospitals and one elderly care institution under a group management structure as of September 30, 2025 [3] - The company emphasizes a "patient-first" core value and implements a "human-centered medical" management model, creating a well-known medical brand called "Lianchi Medical" [3] - As of September 30, 2025, the total building area of the hospitals is approximately 117,893.06 square meters, with a total of 786 registered beds and a team of 341 practicing physicians and assistant doctors [3] Financial Performance - The company recorded revenues of approximately RMB 356.43 million, RMB 418.41 million, and RMB 358.57 million for the years ending December 31, 2023, December 31, 2024, and the nine months ending September 30, 2025, respectively [5][6] - The net profit for the same periods was RMB 56.73 million, RMB 67.59 million, and RMB 55.51 million [7] - Gross profit figures were approximately RMB 117.23 million, RMB 151.14 million, and RMB 127.63 million, with gross profit margins remaining stable at 35.0% for the nine months ending September 30, 2024, and 35.6% for the nine months ending September 30, 2025 [8] Industry Overview - The Chinese healthcare service market has been steadily improving, driven by increasing health awareness, expanded public health insurance coverage, and the rise of chronic diseases [9] - Total healthcare expenditure in China increased from RMB 6.58 trillion in 2019 to RMB 9.76 trillion in 2024, with a compound annual growth rate (CAGR) of 8.2% from 2019 to 2024 [9] - The number of private hospitals in China is projected to grow from 22,424 in 2019 to 26,956 by 2024, with a CAGR of 3.8% [15] Competitive Position - Lianchi Hospital's Zibo Lianchi Orthopedic Hospital ranks first in Shandong Province and third nationally in terms of private hospital knee surgery volume for 2024 [4] - The Chongqing Great Wall Orthopedic Hospital is ranked first among private orthopedic specialty hospitals in Southwest China based on revenue for 2024 [4]